Show simple item record

dc.contributor.authorBarrett-Lee, P J
dc.contributor.authorDixon, J M
dc.contributor.authorFarrell, Carole
dc.contributor.authorJones, A
dc.contributor.authorLeonard, R
dc.contributor.authorMurray, N
dc.contributor.authorPalmieri, C
dc.contributor.authorPlummer, C J
dc.contributor.authorStanley, A
dc.contributor.authorVerrill, Mark W
dc.date.accessioned2009-11-02T14:45:47Z
dc.date.available2009-11-02T14:45:47Z
dc.date.issued2009-05
dc.identifier.citationExpert opinion on the use of anthracyclines in patients with advanced breast cancer at cardiac risk. 2009, 20 (5):816-27 Ann. Oncol.en
dc.identifier.issn1569-8041
dc.identifier.pmid19153118
dc.identifier.doi10.1093/annonc/mdn728
dc.identifier.urihttp://hdl.handle.net/10541/85170
dc.description.abstractAnthracyclines are considered to be among the most active agents for the treatment of breast cancer. However, their use is limited by cumulative, dose-related cardiotoxicity. Such cardiotoxicity results in a permanent loss of cardiac myocytes and a progressive reduction in cardiac function following each subsequent dose of anthracycline. Initially, damage to the heart is subclinical; however, increasingly impaired cardiac function can result in cardiovascular symptoms, with serious cardiac injury resulting in chronic heart failure. Since the early detection and treatment of cardiotoxicity can reduce its clinical effects, it is important that oncologists are aware of these adverse effects and manage them appropriately. This review examines the risk factors for anthracycline-associated cardiotoxicity and offers recommendations on strategies to reduce the cardiotoxicity of anthracyclines in the management of patients with advanced breast cancer.
dc.language.isoenen
dc.subjectBreast Canceren
dc.subject.meshAnthracyclines
dc.subject.meshAntibiotics, Antineoplastic
dc.subject.meshBreast Neoplasms
dc.subject.meshDose-Response Relationship, Drug
dc.subject.meshDrug Monitoring
dc.subject.meshFemale
dc.subject.meshHeart Diseases
dc.subject.meshHumans
dc.subject.meshPatient Selection
dc.subject.meshPractice Guidelines as Topic
dc.subject.meshRisk Assessment
dc.subject.meshRisk Factors
dc.titleExpert opinion on the use of anthracyclines in patients with advanced breast cancer at cardiac risk.en
dc.typeArticleen
dc.contributor.departmentBreast Unit, Velindre Cancer Centre, Cardiff, UK. peter.barrett-lee@velindre-tr.wales.nhs.uken
dc.identifier.journalAnnals of Oncologyen
html.description.abstractAnthracyclines are considered to be among the most active agents for the treatment of breast cancer. However, their use is limited by cumulative, dose-related cardiotoxicity. Such cardiotoxicity results in a permanent loss of cardiac myocytes and a progressive reduction in cardiac function following each subsequent dose of anthracycline. Initially, damage to the heart is subclinical; however, increasingly impaired cardiac function can result in cardiovascular symptoms, with serious cardiac injury resulting in chronic heart failure. Since the early detection and treatment of cardiotoxicity can reduce its clinical effects, it is important that oncologists are aware of these adverse effects and manage them appropriately. This review examines the risk factors for anthracycline-associated cardiotoxicity and offers recommendations on strategies to reduce the cardiotoxicity of anthracyclines in the management of patients with advanced breast cancer.


This item appears in the following Collection(s)

Show simple item record